Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience

Department of Endocrinology and Metabolism, F5-171 Academic Medical Center, University of Amsterdam, Meibergdreef 5, 1105 AZ Amsterdam, The Netherlands. m.f.prummel@amc.uva.nl

To improve management of patients with Graves' orbitopathy, a multi-center collaborative approach is necessary in order to have large enough sample sizes for meaningful randomized clinical trials. This is hampered by a lack of consensus on how to investigate the eye condition. The European Group on Graves' Orbitopathy aims to overcome this and has designed a preliminary case record form (CRF) to assess Graves' orbitopathy patients. This form was used in this first multi-center study. AIM: To investigate patient characteristics and treatment strategies in 152 new consecutively referred patients with thyroid eye disease seen in nine large European referral centers. METHODS: Newly referred patients with Graves' orbitopathy were included who were seen between September and December 2000. Demographic data and a complete ophthalmological assessment were recorded. RESULTS: One-hundred and fifty-two patients (77% females) were included. Diabetes was present in 9%, and glaucoma or cataract in 14% of patients. Forty percent were current smokers, 9% also had dermopathy, and only 33% reported a positive family history of thyroid disease. Mild eye disease was seen in 40%, moderately severe eye disease was seen in 33% and severe eye disease was seen in 28% of patients. Soft tissue involvement was the most frequent abnormality (seen in 75%), proptosis > or =21 mm was found in 63%, eye motility dysfunction in 49%, keratopathy in 16% and optic nerve involvement was found in 21% of patients. According to the clinical impression, 60% had active eye disease. Immunosuppressive treatment was planned more frequently in active patients (57/86; 66%) than in inactive patients (5/57, 9%; Chi-square 46.16; P<0.02). There were no important differences among the eight centers regarding the severity and the activity of their patients. CONCLUSIONS: In view of the large number of patients recruited in only 4 months, multi-center studies in the eight EUGOGO centers appear to be feasible.

This article has been cited by other articles:

				K. K. L. Chong, S. W. Y. Chiang, G. W. K. Wong, P. O. S. Tam, T.-K. Ng, Y.-J. Hu, G. H. F. Yam, D. S. C. Lam, and C.-P. Pang Association of CTLA-4 and IL-13 Gene Polymorphisms with Graves' Disease and Ophthalmopathy in Chinese Children Invest. Ophthalmol. Vis. Sci., June 1, 2008; 49(6): 2409 - 2415. [Abstract] [Full Text] [PDF]

				E B. Y. Konuk, O. Konuk, M. Misirlioglu, A. Menevse, and M. Unal Expression of cyclooxygenase-2 in orbital fibroadipose connective tissues of Graves' ophthalmopathy patients. Eur. J. Endocrinol., November 1, 2006; 155(5): 681 - 685. [Abstract] [Full Text] [PDF]

				The European Group on Graves' Orbitopathy (EUGOGO), W M Wiersinga, P Perros, G J Kahaly, M P Mourits, L Baldeschi, K Boboridis, A Boschi, A J Dickinson, P Kendall-Taylor, et al. Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers Eur. J. Endocrinol., September 1, 2006; 155(3): 387 - 389. [Full Text] [PDF]

				G E Krassas, M Segni, and W M Wiersinga Childhood Graves' ophthalmopathy: results of a European questionnaire study Eur. J. Endocrinol., October 1, 2005; 153(4): 515 - 521. [Abstract] [Full Text] [PDF]

				G. J. Kahaly, S. Pitz, G. Hommel, and M. Dittmar Randomized, Single Blind Trial of Intravenous versus Oral Steroid Monotherapy in Graves' Orbitopathy J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5234 - 5240. [Abstract] [Full Text] [PDF]

				J. L. Wemeau, P. Caron, A. Beckers, V. Rohmer, J. Orgiazzi, F. Borson-Chazot, M. Nocaudie, P. Perimenis, S. Bisot-Locard, I. Bourdeix, et al. Octreotide (Long-Acting Release Formulation) Treatment in Patients with Graves' Orbitopathy: Clinical Results of a Four-Month, Randomized, Placebo-Controlled, Double-Blind Study J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 841 - 848. [Abstract] [Full Text] [PDF]